Cardiology · Heart FailureRegulatory Approvalcommercialmid-term

Torrent Pharmaceuticals submits ANDA for Vericiguat

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Torrent Pharmaceuticals2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 12:33:38 AM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of an ANDA for Vericiguat by Torrent Pharmaceuticals introduces a potential generic competitor in the heart failure market. This could disrupt pricing and market share for existing therapies, necessitating strategic adjustments from incumbent companies. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 14 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of a new generic entrant on market dynamics and pricing strategies. The strongest clinical anchor is Boston Medical Center Ultrasound Decongestion Study in Heart Failure (ClinicalTrials.gov), sub-indication match (cardiology). In cardiology, 5 regulatory and 2 competitive items passed relevance filtering for Torrent Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This submission may position Torrent to compete in the heart failure market, potentially impacting existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). The FDA's review process for the ANDA will determine the timeline for market entry, which could influence competitive dynamics and regulatory compliance for existing products.

Key Risks

Elevated medium regulatory exposure for Torrent Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Torrent Pharmaceuticals through agency review timelines and labeling constraints if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Boston Medical Center Ultrasound Decongestion Study in Heart Failure) could weigh on Torrent Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III) could weigh on Torrent Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of a generic version of Vericiguat could significantly reduce prices and affect the revenue streams of branded competitors in the heart failure segment.
Upside for Torrent Pharmaceuticals may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Upside for Torrent Pharmaceuticals may improve if PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the implications of a new generic entrant on market dynamics and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review process and potential approval timeline for ANDA220221.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — VERICIGUAT (ORIG)
FDAmedium relevance
Entity match (torrent pharmaceuticals); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — VERICIGUAT (ORIG)
FDAmedium relevance
Entity match (torrent pharmaceuticals); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Boston Medical Center Ultrasound Decongestion Study in Heart Failure
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
An Optimization Pilot to Optimize An Early Palliative Care Intervention for Advanced Heart Failure
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Prospective Cohort of Acute Cardiology Referrals in an Ambulatory Day-Hospital Setting
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Cardiology Biobank Registry
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View source
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerlow relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Torrent Pharmaceuticals
Vericiguat

Commercial impact

high

The entry of a generic version of Vericiguat could significantly reduce prices and affect the revenue streams of branded competitors in the heart failure segment.

Regulatory impact

medium

The FDA's review process for the ANDA will determine the timeline for market entry, which could influence competitive dynamics and regulatory compliance for existing products.

What to watch

Monitor the FDA's review process and potential approval timeline for ANDA220221.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.